Cardiovascular Health

Experts discussed the promising future of pericarditis treatment.

The data emphasize the idea that there are no safe exposure limits as well as the need for guidelines.

New findings question the integrity of ticagrelor's clinical trials, raising safety concerns and impacting its use in cardiovascular care.

Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis.

Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.

Health care professionals are encouraged to educate patients on potential cannabis-related risks to cardiovascular health.

New research reveals that bedtime antihypertensive dosing does not improve cardiovascular outcomes in frail older adults, emphasizing safety over timing.

Diet influences blood pressure, cholesterol levels, and overall heart function.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

Pharmacists play a critical role in managing complex pericarditis cases.

Pharmacists have a unique opportunity to improve cardiovascular outcomes by integrating medication management with food-as-medicine approaches.

The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy.

Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.

Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions.

Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction considerations, and special management factors in patients with comorbidities.

GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic kidney disease, and cardiovascular events, with evidence suggesting that some of these benefits may occur independently of weight loss.

The approval is based on findings from the INSPIRE trial, where treprostinil demonstrated efficacy in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure.

The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology.

Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota

Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.

Maternal cardiometabolic issues during pregnancy significantly elevate children's blood pressure, highlighting the need for preventive health measures.

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

The 12.5-mg dose tablet enhances hypertension treatment options and reduces adverse effects for patients.

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.